Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016’, provides an overview of the Herpes Simplex Virus (HSV) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Herpes Simplex Virus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Simplex Virus (HSV) Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Virus (HSV) Infections
- The report reviews pipeline therapeutics for Herpes Simplex Virus (HSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Herpes Simplex Virus (HSV) Infections therapeutics and enlists all their major and minor projects
- The report assesses Herpes Simplex Virus (HSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Herpes Simplex Virus (HSV) Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Virus (HSV) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Herpes Simplex Virus (HSV) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
Introduction 5
Herpes Simplex Virus (HSV) Infections Overview 6
Therapeutics Development 7
Herpes Simplex Virus (HSV) Infections - Therapeutics under Development by Companies 9
Herpes Simplex Virus (HSV) Infections - Therapeutics under Investigation by Universities/Institutes 12
Herpes Simplex Virus (HSV) Infections - Pipeline Products Glance 13
Herpes Simplex Virus (HSV) Infections - Products under Development by Companies 16
Herpes Simplex Virus (HSV) Infections - Products under Investigation by Universities/Institutes 19
Herpes Simplex Virus (HSV) Infections - Companies Involved in Therapeutics Development 20
Herpes Simplex Virus (HSV) Infections - Therapeutics Assessment 60
Drug Profiles 70
Herpes Simplex Virus (HSV) Infections - Recent Pipeline Updates 139
Herpes Simplex Virus (HSV) Infections - Dormant Projects 156
Herpes Simplex Virus (HSV) Infections - Discontinued Products 161
Herpes Simplex Virus (HSV) Infections - Product Development Milestones 162
Appendix 169
List Of Tables
List of Tables
Number of Products under Development for Herpes Simplex Virus (HSV) Infections, H1 2016 14
Number of Products under Development for Herpes Simplex Virus (HSV) Infections - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Development by Companies, H1 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Comparative Analysis by Late Stage Development, H1 2016 20
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Development, H1 2016 22
Products under Development by Companies, H1 2016 23
Products under Development by Companies, H1 2016 (Contd..1) 24
Products under Development by Companies, H1 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2016 26
Herpes Simplex Virus (HSV) Infections - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 27
Herpes Simplex Virus (HSV) Infections - Pipeline by Admedus Ltd, H1 2016 28
Herpes Simplex Virus (HSV) Infections - Pipeline by AiCuris GmbH & Co. KG, H1 2016 29
Herpes Simplex Virus (HSV) Infections - Pipeline by Almirall, S.A., H1 2016 30
Herpes Simplex Virus (HSV) Infections - Pipeline by Astellas Pharma Inc., H1 2016 31
Herpes Simplex Virus (HSV) Infections - Pipeline by Beech Tree Labs, Inc., H1 2016 32
Herpes Simplex Virus (HSV) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 33
Herpes Simplex Virus (HSV) Infections - Pipeline by BioApex, s.r.o., H1 2016 34
Herpes Simplex Virus (HSV) Infections - Pipeline by CEL-SCI Corporation, H1 2016 35
Herpes Simplex Virus (HSV) Infections - Pipeline by Editas Medicine, Inc., H1 2016 36
Herpes Simplex Virus (HSV) Infections - Pipeline by Epiphany Biosciences, Inc., H1 2016 37
Herpes Simplex Virus (HSV) Infections - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 38
Herpes Simplex Virus (HSV) Infections - Pipeline by Genocea Biosciences, Inc., H1 2016 39
Herpes Simplex Virus (HSV) Infections - Pipeline by GenVec, Inc., H1 2016 40
Herpes Simplex Virus (HSV) Infections - Pipeline by Immune Design Corp., H1 2016 41
Herpes Simplex Virus (HSV) Infections - Pipeline by Immunovaccine, Inc., H1 2016 42
Herpes Simplex Virus (HSV) Infections - Pipeline by JN-International Medical Corporation, H1 2016 43
Herpes Simplex Virus (HSV) Infections - Pipeline by Microbiotix, Inc., H1 2016 44
Herpes Simplex Virus (HSV) Infections - Pipeline by Mymetics Corporation, H1 2016 45
Herpes Simplex Virus (HSV) Infections - Pipeline by NanoBio Corporation, H1 2016 46
Herpes Simplex Virus (HSV) Infections - Pipeline by NanoViricides, Inc., H1 2016 47
Herpes Simplex Virus (HSV) Infections - Pipeline by Onxeo SA, H1 2016 48
Herpes Simplex Virus (HSV) Infections - Pipeline by PaxVax, Inc., H1 2016 49
Herpes Simplex Virus (HSV) Infections - Pipeline by Profectus BioSciences, Inc., H1 2016 50
Herpes Simplex Virus (HSV) Infections - Pipeline by ReceptoPharm, Inc., H1 2016 51
Herpes Simplex Virus (HSV) Infections - Pipeline by Redbiotec AG, H1 2016 52
Herpes Simplex Virus (HSV) Infections - Pipeline by Sanofi, H1 2016 53
Herpes Simplex Virus (HSV) Infections - Pipeline by Sanofi Pasteur SA, H1 2016 54
Herpes Simplex Virus (HSV) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 55
Herpes Simplex Virus (HSV) Infections - Pipeline by Shulov Innovative Science Ltd., H1 2016 56
Herpes Simplex Virus (HSV) Infections - Pipeline by Spider Biotech, H1 2016 57
Herpes Simplex Virus (HSV) Infections - Pipeline by Starpharma Holdings Limited, H1 2016 58
Herpes Simplex Virus (HSV) Infections - Pipeline by TGV-Laboratories, H1 2016 59
Herpes Simplex Virus (HSV) Infections - Pipeline by Tomegavax, Inc., H1 2016 60
Herpes Simplex Virus (HSV) Infections - Pipeline by United BioPharma, Inc., H1 2016 61
Herpes Simplex Virus (HSV) Infections - Pipeline by Vaccibody AS, H1 2016 62
Herpes Simplex Virus (HSV) Infections - Pipeline by Vaxart, Inc., H1 2016 63
Herpes Simplex Virus (HSV) Infections - Pipeline by Vical Incorporated, H1 2016 64
Herpes Simplex Virus (HSV) Infections - Pipeline by Vironova AB, H1 2016 65
Herpes Simplex Virus (HSV) Infections - Pipeline by ViroStatics srl, H1 2016 66
Assessment by Monotherapy Products, H1 2016 67
Assessment by Combination Products, H1 2016 68
Number of Products by Stage and Target, H1 2016 70
Number of Products by Stage and Mechanism of Action, H1 2016 72
Number of Products by Stage and Route of Administration, H1 2016 74
Number of Products by Stage and Molecule Type, H1 2016 76
Herpes Simplex Virus (HSV) Infections Therapeutics - Recent Pipeline Updates, H1 2016 146
Herpes Simplex Virus (HSV) Infections - Dormant Projects, H1 2016 163
Herpes Simplex Virus (HSV) Infections - Dormant Projects (Contd..1), H1 2016 164
Herpes Simplex Virus (HSV) Infections - Dormant Projects (Contd..2), H1 2016 165
Herpes Simplex Virus (HSV) Infections - Dormant Projects (Contd..3), H1 2016 166
Herpes Simplex Virus (HSV) Infections - Dormant Projects (Contd..4), H1 2016 167
Herpes Simplex Virus (HSV) Infections - Discontinued Products, H1 2016 168
Lisst Of Figures
List of Figures
Number of Products under Development for Herpes Simplex Virus (HSV) Infections, H1 2016 14
Number of Products under Development for Herpes Simplex Virus (HSV) Infections - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Comparative Analysis by Late Stage Development, H1 2016 20
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Products, H1 2016 22
Assessment by Monotherapy Products, H1 2016 67
Number of Products by Top 10 Targets, H1 2016 69
Number of Products by Stage and Top 10 Targets, H1 2016 69
Number of Products by Top 10 Mechanism of Actions, H1 2016 71
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 71
Number of Products by Top 10 Routes of Administration, H1 2016 73
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 73
Number of Products by Top 10 Molecule Types, H1 2016 75
Number of Products by Stage and Top 10 Molecule Types, H1 2016 75
